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Abstract 
Review on GATA2, with data on DNA, on the 
protein encoded, and where the gene is implicated. 
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Identity 
Other names: MGC2306; NFE1B; 
ENSG00000179348 
HGNC (Hugo): GATA2 




Genomic DNA 13,759bp, 6 exons ((two untranslated 
first exons that utilized differentially and five 
translated exons). 
Transcription 
The distal (IS) exon specifically utilized in 
hematopoietic and neural cells, while the proximal 
(IG) exon is utilized ubiquitously, producing 3383-
bp and 3484-bp transcripts, respectively. These two 
variant transcripts encode the same protein. 




Contains 2 zinc finger domains, ZF1 (aa 294 to 344) 
and ZF2 (aa 349 to 398). 
Expression 
Strictly regulated and tissue specific. Gene activity 
depends on several trans regulators and cis-acting 
regulatory elements scattered in a wide range around 
the gene. 3.1-kbp upstream of IS exon recapitulates 
endogenous Gata2 gene expression in yolk sacs and 
paraaortic splanchnopleura hematopoietic cells in 
mice. An enhancer in 77-kbp upstream of GATA2 
gene and GATA-box-E-box composite element in 
the fourth intron are important in adult 
hematopoiesis and implicated in the leukemogenesis 
in humans (see below). In non-hematopoietic tissues, 
the element in the fourth intron works as an 
endothelial specific enhancer, whereas enhancer(s) 
located between +75- and +113-kbp to the 
translational initiation site are responsible to the 
Gata2 expression in caudal periureteric 
mesenchyme/ urogenital sinus and rostral 
metanephric mesenchyme in mice, respectively. It 
has been considered that currently not-identified 
enhancer(s) for urogenital organs development are 




Binds to the consensus sequence 5'-
(A/T)GATA(A/G)-3'. Transcriptional activator 
which is expressed very early in hematopoiesis and 
plays a role in development and regulation of every 
early pluripotent hematopoietic precursor, but also 
of eosinophils, basophils and mast cells. Early stages 
of erythroid differentiation depends of GATA2, but 
during maturation GATA2 expression decreases 
progressively at the benefit of GATA1. GATA2 
suppresses differentiation of bone marrow 
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mesenchyme stem cells to adipocytes and sustains 
the hematopoietic stem cell environment. GATA2 
also plays roles in development of neural system, 
urogenital organs and vascular system. 
Homology 
Member of the GATA family which contains 6 
known members; only GATA1, GATA2 and 
GATA3 are involved in hematopoiesi 
Mutations 
Germinal 
Loss-of-function mutations and dominant-negative 
mutations have been found as a cause of Familial 
myelodysplastic syndrome (MDS), DCML 
deficiency and Emberger syndrome, which are in a 
group of complex syndromes predisposing to 
leukemia with overlapping clinical features. 
Mutation in GATA-box-E-box composite element in 
the fourth intron, which leads to reduction of 
GATA2 gene expression, has been found in a 
pedigree of MonoMAC syndrome family. 
Somatic 
Chromosomal rearrangements involving the 77-kbp 
upstream region of GATA2 gene on 3q21 and 
MECOM  (EVI1) gene on 3q26 are associated with 
MDS and acute myeloid leukemia (AML). This type 
of hematopoietic malignancies is referred to as 
3q21q26 syndrome.  Mutations are found as a cause 





Immunodeficiency syndrome associated with loss of 
dendritic cells, monocytes, B and NK cells, leading 
to the increasing incidence of mycobacterial, fungal 
and viral infections. This disease occurs sporadically 
or in an autosomal dominant inheritance with 
incomplete penetrance. Patients with DCML 
deficiency have high incidence of developing 
hematopoietic malignancies. DCML deficiency with 
mycobacterium avium complex infection has been 
described as "monoMAC (monocytopenia with 
Mycobacterium avium complex) syndrome". 
Prognosis 
Prone to develop MDS and AML. 
Emberger syndrome 
Disease 
Sporadic or autosomal dominant disease with 
incomplete penetrance, which has a characteristic 
feature of primary lymphoedema with 
myelodysplasia. The lymphedema generally 
confined to the lower limbs and genitals. 
Prognosis 
Prone to develop AML. 
3q21q26 syndrome 
Disease 
Hematopoietic malignancies, including MDS and 
AML, caused by a chromosomal aberration between 
the regions 3q21 and 3q26. The 77-kbp upstream 
region of GATA2 gene on 3q21 is rearranged 
proximal to the Evi1 locus on 3q26 by the 
translocation or inversion. Aberrant expression of 
EVI1 gene lead by the activity of GATA2 enhancer 
is appeared to be involved in the pathogenesis and 





Acute promyelocytic leukaemia (APL) 
Disease 
GATA2 may be involved in APL leukemogenesis by 
physical interaction with the PML component of 
PML-RARa fusion or with the variant PLZF-RARa 




GATA2 is expressed in MDS, but not in normal 
controls; the frequency of expression increases with 
the severity of dysplasia (100% in RAEB/RAEB-T). 
Myeloid transformation of chronic 
myelooid leukemia CML 
Disease 
Out of 85 unselected cases of CML blast 
transformation, 9 showed a GATA2 mutation: 8 with 
a T-->G substitution at aa359 in ZF2 (L359V) and 1 
with a 6 aa deletion (aa 341 to 346) in ZF1. All 9 
transformations were myeloid, with a myeloblastic 
or monoblastic morphology. L359V leads to a gain 
of function of GATA2 protein. 
Aplastic anemia (AA) 
Disease 
Hypothetical. In knockout mice, GATA2 
haploinsufficiency leads to a decrease of 
hematopoietic stem cells number and efficiency. In 
human, GATA2 mRNA expression is largely 
reduced in patients with AA. 
Prostate cancer 
Disease 
High expression of GATA2 is associated with 
aggressiveness, high metastasis ratio and resistance 
for therapy in prostate cancer through, in part, the 
activation of androgen-receptor target genes in 
ligand-independent pathway. 










Non-small cell lung cancer 
Disease 
GATA2 is required for the survival of Ras-mediated 
NSCLC by controlling IL-1/NF-κB signaling. 
Knockdown of GATA2 expression lead to a 
reduction of tumor burden in mouse model of 
NSCLC, suggesting that GATA2 is a therapeutic 
target of Ras mutant cancers. 
Glioma 
Disease 
The level of GATA2 expression that might be 
regulated by EGFR/ERK signaling pathway is 
correlated with prognosis of glioma patients. 
Neuroblastoma 
Disease 
The expression level of GATA2 is reverse-correlated 
with aggressiveness, as GATA2 may negatively 
regulate proliferation of neuroblastoma cells. 
Renal cell carcinoma (RCC) 
Disease 
The expression level of GATA2 is reverse-correlated 
with aggressiveness, possibility of metastasis, and 
risk of recurrence in clear cell RCC. 
Hepatocellular carcinoma 
Disease 
The expression level of GATA2 is reverse-correlated 
with poor prognosis of hepatocellular carcinoma. 
Knockdown of GATA2 expression enhances the 




High level of GATA2 expression is correlated with 
aggressive feature, high recurrence rate and poor 
outcome of colorectal cancer. 
Breast cancer 
Disease 
Roles of GATA2 in pathogenesis of breast cancer are 
contraversial. Reports describing that GATA2 level 
was increased in breast cancer showed that GATA2 
might be related to tumor progression by repressing 
PTEN activity and/or promoting expression of 
aromatase gene, whereas another report showed that 
the expression GATA2 gene was silenced by 
aberrant hyper-methylation of GATA2 promoter 
region. 
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